Watch NVAX. Know when insiders buy.
One email the day a filing lands. Free.
NVAX
NOVAVAX INC
10.55
+0.14 +1.34%
USD · close Sep 23
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
43
WATCH · shorts 43
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1.7BP/E —DIV YIELD —FCF YIELD -2.42%REV TTM $413.8M −61.6%NET INCOME −$247.7M −158.6%NET DEBT $100M52W 6.22 – 11.19SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $56.7M | −76.3% | 74.9% | −$54.9M | −$53.4M | −150.1% | -0.32 | −$72.8M | $588K | −$73.4M | Aug 6 |
| Q1 2026 · Mar 31 | $139.5M | −79.1% | 78.0% | −$15.4M | −$9.5M | −101.8% | -0.06 | −$32.4M | $1.3M | −$33.7M | May 6 |
| Q4 2025 · Dec 31derived | $147.1M | +66.6% | 85.0% | $14.2M | $17.5M | — | 0.05 | −$39.5M | $2.1M | −$41.6M | Feb 26 |
| Q3 2025 · Sep 30 | $70.4M | −16.6% | 69.5% | −$178M | −$202.4M | — | -1.25 | $107.8M | $1.4M | $106.4M | Nov 6 |
| Q2 2025 · Jun 30 | $239.2M | −42.4% | 93.6% | $101.1M | $106.5M | −34.4% | 0.62 | −$127.5M | $527K | −$128M | Aug 6 |
| Q1 2025 · Mar 31 | $666.7M | +610.3% | 97.9% | $515.5M | $518.6M | — | 2.93 | −$185.5M | $1.6M | −$187.1M | May 6 |
| Q4 2024 · Dec 31derived | $88.3M | −69.7% | 58.5% | −$131.1M | −$81M | — | -0.52 | −$173.2M | $1.9M | −$175.1M | Feb 26 |
| Q3 2024 · Sep 30 | $84.5M | −54.8% | 28.3% | −$134M | −$121.3M | — | -0.76 | −$144.8M | $1.4M | −$146.2M | Nov 6 |
| Q2 2024 · Jun 30 | $415.5M | — | 88.9% | $161M | $162.4M | — | 0.99 | $314.3M | $2.9M | $311.4M | Aug 6 |
| Q1 2024 · Mar 31 | $93.9M | — | 36.9% | −$144.8M | −$147.6M | — | -1.05 | −$83.6M | $6.9M | −$90.4M | May 8 |
| Q4 2023 · Dec 31derived | $291.3M | — | 46.8% | −$183.6M | −$178.4M | — | -1.47 | −$176.8M | $8.8M | −$185.6M | Feb 26 |
| Q3 2023 · Sep 30 | $187M | — | 47.1% | −$125.6M | −$130.8M | — | -1.26 | −$39.7M | $18.2M | −$57.8M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $1.1B | 93.5% | $452.8M | $440.3M | 39.2% | 2.58 | −$244.6M | $5.6M | −$250.2M | — | — |
| FY2024 · to Dec 31 | $682.2M | 70.3% | −$248.9M | −$187.5M | -27.5% | -1.23 | −$87.3M | $13.1M | −$100.3M | — | — |
| FY2023 · to Dec 31 | $983.7M | 65.1% | −$566.5M | −$545.1M | -55.4% | -5.41 | −$714M | $53.8M | −$767.7M | — | — |
| FY2022 · to Dec 31 | $2B | 54.5% | −$644.7M | −$657.9M | -33.2% | -8.42 | −$415.9M | $89.1M | −$505M | — | — |
| FY2021 · to Dec 31 | $1.1B | 100.0% | −$1.7B | −$1.7B | -152.1% | -23.44 | $322.9M | $57.5M | $265.5M | — | — |
| FY2020 · to Dec 31 | $475.6M | 100.0% | −$416.7M | −$418.3M | -87.9% | -7.27 | −$42.5M | $54.6M | −$97.2M | — | — |
Every number comes from NOVAVAX INC's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.